In today’s briefing:
- Rio Tinto’s $14.8 Billion Surge: Can Copper & Aluminum Sustain The Momentum?
- Primer: EBOS Group (EBO AU) – Aug 2026
- Primer: Academies Australasia (AKG AU) – Aug 2026
- Primer: Adcorp Australia (AAU AU) – Aug 2026
- Primer: AdVeritas (AV1 AU) – Aug 2026
- Primer: Airtasker (ART AU) – Aug 2026
- Primer: Alice Queen Ltd (AQX AU) – Aug 2026
- Primer: Aldoro Resources Ltd (ARN AU) – Aug 2026
- Primer: Alterity Therapeutics (ATH AU) – Aug 2026
- Primer: Accelerate Resources Ltd (AX8 AU) – Aug 2026
Rio Tinto’s $14.8 Billion Surge: Can Copper & Aluminum Sustain The Momentum?
- Rio Tinto delivered a strong financial performance in the first half of 2026, underpinned by robust operational results, ongoing growth projects, and a continued focus on productivity improvements.
- The company reported a 28% increase in underlying EBITDA to $14.8 billion, driven primarily by higher commodity prices—especially copper and aluminum—and a 75% rise in free cash flow.
- These enhancements supported a 43% increase in the interim dividend to $3.4 billion, reflecting a commitment to shareholder returns amid rising earnings.
Primer: EBOS Group (EBO AU) – Aug 2026
- EBOS Group is the largest and most diversified marketer and distributor of healthcare, medical, and pharmaceutical products in Australasia, with a significant and growing Animal Care division.
- The company is facing near-term earnings pressure due to increased operating costs and the recent loss of a major pharmacy wholesale contract, with analyst expectations for meaningful earnings per share (EPS) growth pushed out to FY28.
- Despite current headwinds, the company offers an attractive dividend yield and possesses long-term growth potential driven by defensive end-markets, strategic investments in logistics, and expansion in its high-growth Animal Care and Medtech businesses.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Academies Australasia (AKG AU) – Aug 2026
- Regulatory Headwinds Creating Uncertainty: Academies Australasia (AKG) is navigating a challenging Australian regulatory environment, particularly concerning international student visa policies and caps on new overseas student commencements (NOSC). These policies directly impact a significant portion of its revenue and create considerable uncertainty for future earnings.
- Precarious Financial Position: The company has a history of net losses and a highly leveraged balance sheet, with significant debt and lease liabilities. While operating cash flow has shown recent improvement, negative free cash flow after lease payments and reliance on director loans are key concerns for financial stability.
- Diversified Operations and Strategic Pivot: AKG operates a diversified portfolio of 18 colleges across Australia and Singapore, offering a wide range of courses. In response to Australian regulatory pressures, management is strategically focusing on growing its Singapore operations and expanding offshore course delivery, which could provide an alternative growth avenue.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Adcorp Australia (AAU AU) – Aug 2026
- Privatized Entity with Limited Transparency: Adcorp Australia was voluntarily delisted from the ASX in December 2019 and now operates as a private entity, Adcorp Australia Pty Limited. This significantly reduces the availability of public financial information and transparency, posing a major challenge for analysis and investment.
- Shift in Business Focus: The company has pivoted from a traditional advertising agency to a ‘workforce solutions’ provider, specializing in contingent staffing and IT recruitment through brands like Paxus and BLU. This aligns it more with the human resources and recruitment industry than the general advertising market.
- Subsidiary of a Foreign Parent: Adcorp Australia is a subsidiary of Adcorp Holdings Limited, a company based in South Africa and listed on the Johannesburg Stock Exchange (JSE). The Australian operations’ performance is consolidated into the parent company’s financials, making standalone assessment difficult. The strategic direction and financial health are heavily dependent on the parent.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: AdVeritas (AV1 AU) – Aug 2026
- AdVeritas is a high-growth, pre-profitability ad-tech company centered on its sole product, TrafficGuard, a SaaS platform for digital ad fraud detection and prevention. The company is experiencing rapid revenue growth, with a 56.87% 3-year CAGR, but faces substantial net losses and negative cash flow as it invests in scaling its global operations.
- The company operates in the large and expanding digital ad fraud market, which is projected to grow significantly as advertisers seek to protect their budgets from invalid traffic. AdVeritas’s strategy focuses on direct enterprise sales, agency partnerships, and a new self-serve platform for SMEs to capture a wider segment of the market.
- Key challenges for investors include the company’s persistent unprofitability, negative gross margins (though improving), and a high valuation on a price-to-sales basis relative to peers. The path to profitability hinges on scaling revenue to outpace high operating costs and achieving positive unit economics.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Airtasker (ART AU) – Aug 2026
- Airtasker is a high-growth online marketplace for local services with a strong position in Australia and is now focused on expanding into the significantly larger UK and US markets.
- The company has demonstrated a robust revenue CAGR and improving monetization rates, although it remains unprofitable due to significant investments in marketing and international expansion.
- Key challenges include achieving profitability in new markets, fending off competition from both direct and indirect substitutes, and navigating the potential disruption of AI in the services sector.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Alice Queen Ltd (AQX AU) – Aug 2026
- Alice Queen is a high-risk, high-reward junior exploration company with a diversified portfolio of gold and copper projects in Australia and Fiji, offering speculative upside potential.
- The flagship Horn Island project in Queensland has a defined JORC-compliant resource, providing a tangible asset and a potential pathway to production, distinguishing it from pure greenfield explorers.
- The company is pre-revenue and reliant on external capital to fund its exploration and development activities, posing a significant funding and dilution risk to shareholders.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Aldoro Resources Ltd (ARN AU) – Aug 2026
- Aldoro Resources is a mineral exploration company primarily focused on critical minerals, with its flagship Kameelburg project in Namibia showing significant potential for rare earth elements (REEs), niobium, and strontium.
- Recent drilling results from the Kameelburg project have substantially increased the mineral resource estimate, positioning it as a globally significant undeveloped REE and strontium deposit.
- The company is in a pre-revenue stage, and its financial performance reflects significant exploration and evaluation expenditures. Future profitability is entirely dependent on the successful development of its exploration projects.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Alterity Therapeutics (ATH AU) – Aug 2026
- Alterity Therapeutics is a late clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, with its lead candidate, ATH434, targeting Multiple System Atrophy (MSA) and other Parkinsonian disorders.
- The company has reported positive Phase 2 data for ATH434 in MSA, demonstrating a favorable safety profile and statistically significant efficacy, and is now advancing towards a pivotal Phase 3 trial after aligning with the U.S. FDA.
- As a pre-revenue company, Alterity’s financial performance is characterized by net losses and negative cash flow driven by R&D expenses, making its valuation and future success highly dependent on the clinical and regulatory outcomes of ATH434.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Primer: Accelerate Resources Ltd (AX8 AU) – Aug 2026
- Accelerate Resources is a junior exploration company focused on high-impact gold and critical minerals (manganese and lithium) projects in Western Australia, a Tier-1 mining jurisdiction.
- The company’s strategy is centered on a dual-commodity approach, advancing its Woodie Woodie North Manganese Project and various gold projects, while maintaining exposure to lithium. This approach targets commodities essential for both traditional and green-energy markets.
- As a pre-revenue explorer, the company is entirely dependent on capital markets for funding its exploration programs. Its financial performance is characterized by operating losses and negative cash flow, which is typical for its stage of development. Investment success is contingent on exploration discovery and commodity market dynamics.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

